1. Grundy, SM, Stone, NJ, Bailey, AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation. 2019;139(25):e1082-e1143.
Google Scholar | Medline2. Virani, SS, Alonso, A, Aparicio, HJ, et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254-e743.
Google Scholar | Crossref | Medline3. Florentin, M, Kostapanos, MS, Anagnostis, P, Liamis, G. Recent developments in pharmacotherapy for hypertriglyceridemia: What's the current state of the art? Expert Opin Pharmacother. 2020;21(1):107-120.
Google Scholar | Crossref | Medline4. Miller, M, Stone, NJ, Ballantyne, C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123(20):2292-2333.
Google Scholar | Crossref | Medline | ISI5. Hokanson, JE, Austin, MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3(2):213-219.
Google Scholar | SAGE Journals6. Nordestgaard, BG, Benn, M, Schnohr, P, Tybjaerg-Hansen, A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299-308.
Google Scholar | Crossref | Medline | ISI7. Vallejo-Vaz, AJ, Corral, P, Schreier, L, Ray, KK. Triglycerides and residual risk. Curr Opin Endocrinol Diabetes Obes. 2020;27(2):95-103.
Google Scholar | Crossref | Medline8. Fruchart, JC, Sacks, FM, Hermans, MP, et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res. 2008;5(4):319-335.
Google Scholar | SAGE Journals | ISI9. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration , et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 2010;375(9726):1634-1639.
Google Scholar | Crossref | Medline10. Virani, SS, Morris, PB, Agarwala, A, et al. ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;78(9):960-993.
Google Scholar | Crossref | Medline11. Valdivielso, P, Ramirez-Bueno, A, Ewald, N. Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med. 2014;25(8):689-694.
Google Scholar | Crossref | Medline12. Navina, S, Acharya, C, DeLany, JP, et al. Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. Sci Transl Med. 2011;3(107):107ra110.
Google Scholar | Crossref | Medline13. Yang, F, Wang, Y, Sternfeld, L, et al. The role of free fatty acids, pancreatic lipase and Ca+ signalling in injury of isolated acinar cells and pancreatitis model in lipoprotein lipase-deficient mice. Acta Physiol. 2009;195(1):13-28.
Google Scholar | Crossref | Medline14. Skulas-Ray, AC, Wilson, PWF, Harris, WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140(12):e673-e691.
Google Scholar | Crossref | Medline15. LaRosa, JC, Grundy, SM, Waters, DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-1435.
Google Scholar | Crossref | Medline | ISI16. Faergeman, O, Holme, I, Fayyad, R, et al. Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease. Am J Cardiol. 2009;104(4):459-463.
Google Scholar | Crossref | Medline | ISI17. Ference, BA, Kastelein, JJP, Ray, KK, et al. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA. 2019;321(4):364-373.
Google Scholar | Crossref | Medline18. Shapiro, MD, Fazio, S. Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease. F1000Res. 2017;6:134.
Google Scholar | Crossref | Medline19. Bradberry, JC, Hilleman, DE. Overview of omega-3 fatty acid therapies. PT. 2013;38(11):681-691.
Google Scholar | Medline20. Harris, WS, Bulchandani, D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006;17(4):387-393.
Google Scholar | Crossref | Medline21. Shearer, GC, Savinova, OV, Harris, WS. Fish oil -- how does it reduce plasma triglycerides? Biochim Biophys Acta. 2012;1821(5):843-851.
Google Scholar | Crossref | Medline | ISI22. Abdelhamid, AS, Brown, TJ, Brainard, JS, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020;3:CD003177.
Google Scholar | Medline23. Bhatt, DL, Steg, PG, Miller, M, et al. Cardiovascular risk reduction with icosapent ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22.
Google Scholar | Crossref | Medline24. US Food & Drug Administration . FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups. 2019. https://www.fda.gov/news-events/press-announcements/fda-approves-use-drug-reduce-risk-cardiovascular-events-certain-adult-patient-groups. Accessed March 30, 2021.
Google Scholar25. Kastelein, JJ, Maki, KC, Susekov, A, et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol. 2014;8(1):94-106.
Google Scholar | Crossref | Medline26. Blair, HA, Dhillon, S. Omega-3 carboxylic acids (Epanova): a review of its use in patients with severe hypertriglyceridemia. Am J Cardiovasc Drugs. 2014;14(5):393-400.
Google Scholar | Crossref | Medline27. Nicholls, SJ, Lincoff, AM, Bash, D, et al. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clin Cardiol. 2018;41(10):1281-1288.
Google Scholar | Crossref | Medline28. Nicholls, SJ, Lincoff, AM, Garcia, M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial. JAMA. 2020;324(22):2268-2280.
Google Scholar | Crossref | Medline29. ClinicalTrials.gov . TRIal for efficacy of capre on hyperTriglyceridemiA (TRIFECTA). October 20, 2011. https://www.clinicaltrials.gov/ct2/show/NCT01455844. Accessed February 4, 2021.
Google Scholar30. ClinicalTrials.gov . Assess the safety and efficacy of NKPL66 (CaPre™) in the treatment of mild-to-high hypertriglyceridemia. January 24, 2012. https://clinicaltrials.gov/ct2/show/NCT01516151. Accessed .
Google Scholar31. Acasti Pharma . Form 10-K. Annual report persuant to section 13 and 15(d) of the Securities Exchange Act of 1934. June 29, 2020. https://www.acastipharma.com/en/investors/regulatory-filings/annual-reports/content/0001171843-20-004613/0001171843-20-004613.pdf. Accessed March 30, 2021.
Google Scholar32. ClinicalTrials.gov . A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 1). January 12, 2018. https://www.clinicaltrials.gov/ct2/show/NCT03398005. Accessed February 4, 2021.
Google Scholar33. ClinicalTrials.gov . A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2). December 5, 2017. https://www.clinicaltrials.gov/ct2/show/NCT03361501. Accessed February 4, 2021.
Google Scholar34. Acasti Pharma . Acasti pharma reports topline results for TRILOGY 1 phase 3 trial of CaPre. January 13, 2020. https://www.acastipharma.com/en/investors/news-events/press-releases/detail/173/acasti-pharma-reports-topline-results-for-trilogy-1-phase-3. Accessed March 30, 2021.
Google Scholar35. Acasti Pharma . Acasti pharma provides update on TRILOGY 1 and TRILOGY 2 phase 3 trials of CaPre. February 10, 2020. https://www.acastipharma.com/en/investors/news-events/press-releases/detail/174/acasti-pharma-provides-update-on-trilogy-1-and-trilogy-2. Accessed March 30, 2021.
Google Scholar36. Acasti Pharma . Acasti pharma reports topline triglyceride results from phase 3 TRILOGY 2 study of CaPre in patients with severe hypertriglyceridemia. August 31, 2020. https://www.acastipharma.com/en/investors/news-events/press-releases/detail/186/acasti-pharma-reports-topline-triglyceride-results-from. Accessed March 30, 2021.
Google Scholar37. Climax, J, Newsome, PN, Hamza, M, et al. Effects of Epeleuton, a novel synthetic second-generation n-3 fatty acid, on non-alcoholic fatty liver disease, triglycerides, glycemic control, and cardiometabolic and inflammatory markers. J Am Heart Assoc. 2020;9(16)-e016334.
Google Scholar | Crossref | Medline38. ClinicalTrials.gov . Safety and efficacy study of orally administered DS102 in healthy subjects. February 4, 2016. https://clinicaltrials.gov/ct2/show/NCT02673593. Accessed February 4, 2021.
Google Scholar39. ClinicalTrials.gov . TRIgyceride and glucose control with epeleuton in metabolic syndrome patients (TRIAGE). April 28, 2020. https://www.clinicaltrials.gov/ct2/show/NCT04365400. Accessed February 4, 2021.
Google Scholar40. Triglide (fenofibrate) [prescribing information]. East Brunswick, NJ: Casper Pharma LLC; 2021.
Google Scholar41. Fenoglide (fenofibrate) [prescribing information]. Bridgewater, NJ: Salix Pharmaceuticals; 2021.
Google Scholar42. Tricor (fenofibrate) [prescribing information]. North Chicago, IL: AbbVie Inc.; 2021.
Google Scholar43. Lopid (gemofibrozil) [prescribing information]. New York, NY: Parke-Davis; 2020.
Google Scholar44. Fruchart, JC, Santos, RD, Aguilar-Salinas, C, et al. The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. Cardiovasc Diabetol. 2019;18(1):71.
Google Scholar | Medline45. Fruchart, JC . Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc Diabetol. 2017;16(1):124.
Google Scholar | Crossref | Medline46. Raza-Iqbal, S, Tanaka, T, Anai, M, et al. Transcriptome analysis of K-877 (a novel selective PPARalpha modulator (SPPARMalpha))-regulated genes in primary human hepatocytes and the mouse liver. J Atheroscler Thromb. 2015;22(8):754-772.
Google Scholar | Crossref | Medline47. Ishibashi, S, Yamashita, S, Arai, H, et al. Effects of K-877, a novel selective PPARalpha modulator (SPPARMalpha), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis. 2016;249:36-43.
Google Scholar | Crossref | Medline48. Ishibashi, S, Arai, H, Yokote, K, et al. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor alpha modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol. 2018;12(1):173-184.
Google Scholar | Crossref | Medline49. Arai, H, Yamashita, S, Yokote, K, et al. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial. J Atheroscler Thromb. 2018;25(6):521-538.
Google Scholar | Crossref | Medline50. Arai, H, Yamashita, S, Yokote, K, et al. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor alpha modulator (SPPARMalpha), in combination with statin treatment: two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis. 2017;261:144-152.
Google Scholar | Crossref | Medline51. Araki, E, Yamashita, S, Arai, H, et al. Effects of pemafibrate, a novel selective PPARalpha modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2018;41(3):538-546.
Google Scholar | Crossref | Medline52. Araki, E, Yamashita, S, Arai, H, et al. Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52-week data from the PROVIDE study. Diabetes Obes Metab. 2019;21(7):1737-1744.